Introduction
============

Remifentanil\'s titratability and rapid organ-independent metabolism make it ideally suited for use in critically ill patients. Establishing safety in this population is important as studies of remifentanil for greater than 3 days are limited. This study compared the safety and efficacy of remifentanil-based analgesia and sedation (RBA) with hypnotic-based sedation (HBS), in 105 ICU patients with medical conditions requiring long-term (up to 10 days) mechanical ventilation.

Methods
=======

One hundred and five patients were randomised to receive either RBA or HBS. Remifentanil infusion started at 6--9 μg/kg/hour and was titrated to effect to provide optimal analgesia and sedation. Supplemental midazolam (MID) bolus was introduced to remifentanil at a rate of 12--18 μg/kg/hour. HBS (MID + fentanyl or morphine at investigator\'s choice) was administered according to routine clinical practice. Adverse events (AEs) were recorded throughout the treatment and post-treatment period.

Results
=======

No clinical differences were observed in the incidence of adverse events. Seventeen patients received RBA and 16 patients received HBS for at least 10 days. Table [1](#T1){ref-type="table"} presents the AEs.

                          RBA (*n*= 57)   HBS (*n*= 48)
  ----------------------- --------------- ---------------
  Total AEs               19 (33%)        16 (33%)
  Total serious AEs       7 (12%)         6 (13%)
  Hypotension\*           3 (5%)          4 (8%)
  Atrial fibrillation\*   4 (7%)          2 (4%)
  Septic shock\*          0               3 (6%)
  Vomiting\*              3 (5%)          0

\*Most common AEs.

Conclusions
===========

Remifentanil is well tolerated when used for periods of up to 10 days in intensive care patients on mechanical ventilation. No adverse events relating to prolonged recovery from mu-opioid effects were reported.
